Search Results for "Xarelto Vs Pradaxa"

17:55 EDT 7th July 2015 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Boehringer submits Pradaxa antidote to regulators

A new product which can rapidly reverse the effects of Boehringer Ingelheim's (BI) anticoagulant Pradaxa has been filed with regulators in the US and Europe.The drug, idarucizumab, is the first to be ...

Xarelto Lawsuit News: Bayer and Johnson & Johnson Pursue Additional FDA Approvals for Xarelto while Cases against the Blood Thinner are Consolidated into Multidistrict Litigation, Says Lawsuitsettlementnews.com

PHILADELPHIA, Feb. 25, 2015 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that a recent announcement by Ba...

Physician Views: How do European cardiologists perceive oral anticoagulants versus warfarin? โ€“ Is Eliquis, Pradaxa or Xarelto their favoured option?

Recently added to the BioPortfolio report store, Physician Views: How do European cardiologists perceive oral anticoagulants versus warfarin? โ€“ Is Eliquis, Pradaxa or Xarelto their favoured option?...

Legal-Bay Lawsuit Settlement Funding Reports Bayer and Johnson & Johnson to Pursue Further FDA Approvals for Xarelto while Cases against the Drug are Consolidated into Multidistrict Litigation

PHILADELPHIA, March 9, 2015 /PRNewswire/ -- Legal-Bay LLC, The Lawsuit Settlement Funding Company, reports that Bayer and Johnson & Johnson made a recent announcement that they will pursue ad...

Xarelto News Update: New Court Documents Issued in Two Courts, Says Lawsuitsettlementnews.com

NEW ORLEANS, April 2, 2015 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that two new court documents have...

Xarelto News Update: Court Meeting Took Place to Identify Potential Plaintiffs for Possible Inclusion in Upcoming Bellwether Trials, Says Lawsuitsettlementnews.com

NEW ORLEANS, July 1, 2015 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that in the most recent news of the Xar...

Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE

LOS ANGELES, April 21, 2015 /PRNewswire/ -- Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that Pradaxa's maker, Boehringer Ingelheim Pharmaceuticals, is seeking FDA appro...

FDA files sDNA for Pradaxa

Ryan ChavisA new indication for Boehringer Ingelheim Pharmaceuticals's Pradaxa may be on the horizon.  read more

Matching PubMed Articles

The New or Non-Vitamin K Antagonist Oral Anticoagulants: What Have We Learned Since Their Debut.

One of the major advances in the management of thrombosis is arguably the introduction of the new non-vitamin K antagonist oral anticoagulants (NOACs). These are small molecules, designed to directly ...

SPONTANEOUS CHOROIDAL HEMORRHAGE IN A PATIENT ON DABIGATRAN ETEXILATE (PRADAXA).

To report the first known case of spontaneous choroidals in association with a patient on dabigatran etexilate.

Structure-guided residence time optimization of a dabigatran reversal agent.

Novel oral anticoagulants are effective and safe alternatives to vitamin-K antagonists for anticoagulation therapy. However, anticoagulation therapy in general is associated with an elevated risk of b...

More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.

The number of patients on antithrombotic treatment due to atrial fibrillation and venous thromboembolism is increasing fast due to an aging population. A growing proportion will be treated with novel ...

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement